ALDX Aldeyra Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ALDX

Price (delayed)

$1.78

Market cap

$107.37M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.45

Enterprise value

$57.88M

?
Relative Growth: Rel. Growth: 21
Relative Strength: Rel. Strength: 2
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 12

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's ...

Highlights
The company's EPS has surged by 54% YoY and by 20% QoQ
The net income has soared by 53% YoY and by 19% from the previous quarter
The quick ratio has dropped by 58% year-on-year but it is up by 6% since the previous quarter
ALDX's equity is down by 34% year-on-year and by 4.7% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.aldeyra.com
Peers: REGN

Key stats

What are the main financial stats of ALDX

ALDX stock price

How has the Aldeyra Therapeutics stock price performed over time
Intraday
-4.3%
1 week
1.71%
1 month
9.88%
1 year
-27.94%
YTD
-65.64%
QTD
5.33%

Financial performance

How have Aldeyra Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$28.38M
Net income
-$27.37M
Gross margin
N/A
Net margin
N/A
Aldeyra Therapeutics's operating income has surged by 54% YoY and by 20% QoQ
The net income has soared by 53% YoY and by 19% from the previous quarter

Price vs fundamentals

How does ALDX's price correlate with its fundamentals

Growth

What is Aldeyra Therapeutics's growth rate over time

Valuation

What is Aldeyra Therapeutics stock price valuation
P/E
N/A
P/B
2.54
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS has surged by 54% YoY and by 20% QoQ
ALDX's price to book (P/B) is 47% less than its last 4 quarters average of 5.0 and 17% less than its 5-year quarterly average of 3.2
ALDX's equity is down by 34% year-on-year and by 4.7% since the previous quarter

Efficiency

How efficient is Aldeyra Therapeutics business performance
The return on assets has increased by 31% year-on-year and by 12% since the previous quarter
The ROE has grown by 21% YoY and by 10% from the previous quarter

Dividends

What is ALDX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ALDX.

Financial health

How did Aldeyra Therapeutics financials performed over time
The total assets is 173% greater than the total liabilities
The current ratio has dropped by 58% year-on-year but it is up by 5% since the previous quarter
The quick ratio has dropped by 58% year-on-year but it is up by 6% since the previous quarter
Aldeyra Therapeutics's debt is 63% lower than its equity
The company's debt to equity has surged by 54% YoY and by 6% QoQ
ALDX's equity is down by 34% year-on-year and by 4.7% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.